Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Older Patients with Cancer and High-Risk Geriatric Profiles at Greater Risk for Death and Other Adverse Sequelae of COVID-19

Findings from the COVID-19 and Cancer Consortium cohort study
21 Feb 2022
Cancer in Special Situations / Population

In a large study of 5671 older adults with COVID-19 and cancer, performed by the COVID-19 and Cancer Consortium (CCC19), the CCC19 geriatric risk index was associated with poorer outcomes, including clinical complications, hospitalisation, and mortality. A higher CCC19 geriatric risk index was significantly associated with higher COVID-19 severity and 30-day all-cause mortality after adjustment of major prognostic confounding factors and explained the greatest amount of variation in these outcomes compared with all other risk factors. The results suggest that the CCC19 geriatric risk index, using a combination of previously studied poor prognostic factors for COVID-19 mortality, can effectively risk stratify this vulnerable patient population. The findings are published on 14 February 2022 in The Lancet Health Longevity.

The study team explained that older age is associated with poorer COVID-19 outcomes, although the heterogeneity of ageing results in some older adults being at greater risk than others. Despite heightened risk of mortality, there is insufficient understanding of which subpopulations are at high risk for adverse outcomes of COVID-19.

Studies in the general geriatric population have shown that the presence of comorbidities and frailty increase the risk of death and other complications of COVID-19, as do the presence of comorbidities and poor performance status in those with cancer.

The Cancer and Aging Research Group and the International Society of Geriatric Oncology released statements on older people with cancer, but noted that these statements were based on clinical consensus, not robust evidence. As a result, there is an urgent need to determine the effect of COVID-19 in older adults with cancer and identify those most vulnerable for adverse outcomes.

The primary objective of this CCC19 analysis was to determine whether a measure of geriatric risk that combined age, comorbidities, and performance status, could capture risk of severe clinical outcomes among older patients with cancer and COVID-19. The study team also sought to describe the presentation, complications, and effect of COVID-19 on subsequent cancer care among older adults with cancer.

In this CCC19 cohort study, the study team enrolled patients aged 60 years and older with a current or previous cancer diagnosis and a current or previous laboratory-confirmed COVID-19 diagnosis who reported to the CCC19 multinational, multicentre, registry between 17 March 2020 and 6 June 2021. The exposure of interest was the CCC19 geriatric risk index. The primary outcome was COVID-19 severity and the secondary outcome was 30-day all-cause mortality; both were assessed in the full dataset. Adjusted odds ratios (ORs) and 95% confidence intervals (CIs) were estimated from ordinal and binary logistic regression models.

In total, 5671 patients were included in the analysis. Median follow-up time was 56 days, and median age was 72 years (IQR 66–79). The CCC19 geriatric risk index identified 2365 patients (41.7%) as standard risk, 2217 patients (39.1%) as intermediate risk, and 1089 patients (19.2%) as high risk. In addition, 36 patients (0.6%) were excluded due to non-calculable geriatric risk index.

Compared with standard-risk patients, high-risk patients had significantly higher COVID-19 severity (adjusted OR 7.24; 95% CI 6.20–8.45). A total 920 of 5671 patients (16.2%) died within 30 days of a COVID-19 diagnosis, including 161 of 2365 standard-risk patients (6.8%), 409 of 2217 intermediate-risk patients (18.5%), and 350 of 1089 high-risk patients (32.1%). High-risk patients had higher adjusted odds of 30-day mortality (adjusted OR 10.7; 95% CI 8.54–13.5) than standard-risk patients.

The authors concluded that CCC19 geriatric risk index was strongly associated with COVID-19 severity and 30-day mortality. The CCC19 geriatric risk index, based on readily available clinical factors, might provide clinicians with an easy-to-use risk stratification method to identify older adults with cancer most at risk for severe COVID-19, as well as mortality.

The authors commented that despite being a large multicentre study examining a comprehensive cohort of older adults with cancer and COVID-19, this study has several limitations that are inherent to its retrospective registry nature. 

Future research questions include the extent to which vaccines will reduce incidence and severity of COVID-19 in this vulnerable population who might not mount as robust an immune response to vaccination. These studies are ongoing, with encouraging initial results with regard to older adults with cancer. Older adults with cancer should be prioritised for vaccination roll-out.

It is unknown how modifications of anticancer therapy affect cancer control, and whether functional decline due to COVID-19 affects subsequent ability to tolerate cancer therapy in a group who might already have been at high risk for toxicity of therapy.

The study was funded by the US National Institutes of Health National Cancer Institute Cancer Center.  

Reference

Elkrief A, Hennessy C, Kuderer NM, et al. on behalf of the COVID-19 and Cancer Consortium. Geriatric risk factors for serious COVID-19 outcomes among older adults with cancer: a cohort study from the COVID-19 and Cancer Consortium. The Lancet Health Longevity; Published online 14 February 2022. DOI: https://doi.org/10.1016/S2666-7568(22)00009-5

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.